Ligand Pharmaceuticals (NASDAQ:LGND) Director John Kozarich Sells 500 Shares of Stock

Key Points

  • Ligand director Martine Zimmermann sold 2,000 shares for $636,340 at an average price of $318.17, reducing her direct stake by 52.88% to 1,782 shares.
  • Ligand beat quarterly estimates, reporting EPS of $2.67 versus $2.33 expected and revenue of $78.75 million versus $77 million expected; revenue was nevertheless down 31.8% year over year.
  • Analysts maintain a “Moderate Buy” consensus, with an average price target of $355.38; eight analysts rate the stock Buy and one rates it Hold.

Ligand Pharmaceuticals Incorporated (NASDAQ:LGND - Get Free Report) Director John Kozarich sold 500 shares of the firm's stock in a transaction on Thursday, November 12th. The shares were sold at an average price of $325.00, for a total transaction of $162,500.00. Following the completion of the transaction, the director owned 42,122 shares in the company, valued at $13,689,650. The trade was a 1.17% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Ligand Pharmaceuticals Stock Performance

Shares of LGND opened at $301.71 on Tuesday. The company has a market capitalization of $6.03 billion, a PE ratio of 134.69, a price-to-earnings-growth ratio of 5.52 and a beta of 1.16. The company has a debt-to-equity ratio of 0.71, a current ratio of 1.22 and a quick ratio of 1.19. Ligand Pharmaceuticals Incorporated has a one year low of $175.89 and a one year high of $326.63. The company's fifty day moving average price is $302.03 and its 200 day moving average price is $258.58.




Ligand Pharmaceuticals (NASDAQ:LGND - Get Free Report) last released its quarterly earnings results on Thursday, October 29th. The biotechnology company reported $2.67 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $2.33 by $0.34. Ligand Pharmaceuticals had a net margin of 20.27% and a return on equity of 5.22%. The company had revenue of $78.75 million during the quarter, compared to analysts' expectations of $77.00 million. During the same period in the prior year, the company earned $3.09 earnings per share. The business's quarterly revenue was down 31.8% compared to the same quarter last year. As a group, analysts expect that Ligand Pharmaceuticals Incorporated will post 2.35 earnings per share for the current year.

Hedge Funds Weigh In On Ligand Pharmaceuticals

Several large investors have recently bought and sold shares of LGND. Janus Henderson Group PLC boosted its holdings in Ligand Pharmaceuticals by 1.5% in the 1st quarter. Janus Henderson Group PLC now owns 1,009,891 shares of the biotechnology company's stock valued at $201,623,000 after purchasing an additional 14,491 shares during the period. Goldman Sachs Group Inc. grew its position in Ligand Pharmaceuticals by 14.6% in the 3rd quarter. Goldman Sachs Group Inc. now owns 370,529 shares of the biotechnology company's stock worth $115,742,000 after purchasing an additional 47,284 shares during the last quarter. Ranger Investment Management L.P. bought a new position in shares of Ligand Pharmaceuticals during the 2nd quarter worth about $81,424,000. Rice Hall James & Associates LLC increased its holdings in shares of Ligand Pharmaceuticals by 1.4% during the 1st quarter. Rice Hall James & Associates LLC now owns 283,567 shares of the biotechnology company's stock worth $56,614,000 after purchasing an additional 3,940 shares during the period. Finally, Russell Investments Group Ltd. increased its holdings in shares of Ligand Pharmaceuticals by 41.4% during the 3rd quarter. Russell Investments Group Ltd. now owns 170,089 shares of the biotechnology company's stock worth $53,131,000 after purchasing an additional 49,785 shares during the period. 91.28% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several equities analysts recently weighed in on LGND shares. Barclays boosted their price objective on Ligand Pharmaceuticals from $345.00 to $350.00 and gave the stock an "overweight" rating in a research report on Wednesday, November 11th. HC Wainwright restated a "buy" rating and set a $358.00 target price on shares of Ligand Pharmaceuticals in a research note on Thursday, September 24th. Weiss Ratings lowered Ligand Pharmaceuticals from a "buy (b)" rating to a "hold (c)" rating in a report on Monday, November 2nd. Citigroup raised their target price on Ligand Pharmaceuticals from $397.00 to $402.00 and gave the company a "buy" rating in a report on Thursday, November 5th. Finally, Leerink Partners initiated coverage on Ligand Pharmaceuticals in a research report on Friday, August 14th. They issued an "outperform" rating and a $330.00 price target on the stock. Eight equities research analysts have rated the stock with a Buy rating and one has given a Hold rating to the company. Based on data from MarketBeat, Ligand Pharmaceuticals currently has a consensus rating of "Moderate Buy" and an average target price of $355.38.

Check Out Our Latest Analysis on Ligand Pharmaceuticals

About Ligand Pharmaceuticals

(Get Free Report)

Ligand Pharmaceuticals is a biopharmaceutical company that works with pharmaceutical and biotechnology partners to develop and commercialize medicines. Rather than focusing primarily on selling drugs directly, Ligand licenses technologies and drug-development assets and may receive royalties and other payments from partner programs. Its technologies include Captisol, a formulation platform designed to improve the solubility and delivery of certain medicines. Ligand also holds economic interests in a portfolio of partnered products and drug candidates across multiple therapeutic areas.

See Also

Insider Buying and Selling by Quarter for Ligand Pharmaceuticals (NASDAQ:LGND)

This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].

Insider Buying or Selling at Ligand Pharmaceuticals?
Sign-up to receive InsiderTrades.com's daily insider buying and selling report for Ligand Pharmaceuticals and related companies.
Free Insider Buying and Selling Newsletter
Enter your email address below to receive InsiderTrades.com's daily insider buying and selling report.
From Our Partners

Most Read This Month

Recent Articles